Compare LXFR & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LXFR | EOLS |
|---|---|---|
| Founded | 1898 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 459.5M | 529.1M |
| IPO Year | 2002 | 2018 |
| Metric | LXFR | EOLS |
|---|---|---|
| Price | $17.23 | $7.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 390.0K | ★ 601.9K |
| Earning Date | 10-27-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.02% | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $384,600,000.00 | $297,176,000.00 |
| Revenue This Year | N/A | $12.44 |
| Revenue Next Year | $6.26 | $17.37 |
| P/E Ratio | $55.63 | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $11.26 | $3.86 |
| 52 Week High | $19.45 | $9.31 |
| Indicator | LXFR | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 52.14 | 44.69 |
| Support Level | $17.19 | $7.59 |
| Resistance Level | $17.38 | $8.47 |
| Average True Range (ATR) | 0.05 | 0.31 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 31.32 | 43.40 |
Luxfer Holdings PLC is engaged in materials engineering and the manufacture of materials, components, and gas containment products. The company has two reportable segments: Elektron and Gas Cylinders. The Elektron segment produces specialty materials based on magnesium and zirconium for applications in aerospace, defense, automotive, and industrial markets. The Gas Cylinders segment manufactures high-pressure gas containment products using aluminum alloys and carbon composite technologies for use in healthcare, emergency response, aerospace, and alternative fuel transportation markets.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.